Analyst Conference Summary

Gilead Sciences

conference date: October 20, 2009 @ 1:30 PM Pacific Time
for quarter ending: September 30, 2009 (third quarter)

Forward-looking statements

Overview: Continued strong revenue and earnings growth.

Basic data (GAAP) :

Revenues were $1.80 billion, up 9% sequentially from $1.65 billion, and up 31% from $1.37 billion in the year-earlier quarter.

Net income was $673.0 million, up 18% sequentially $571 million, and up 46% from $495.9 million year-earlier.

Earnings per share (EPS) were $0.72, up 18% sequentially from $0.61, and 38% from $0.52 year-earlier.


Raising guidance for product revenues to $6.35 billion, up 25% y/y. 76 to 78% non-GAAP product gross margin.

Conference Highlights:

Record revenues with market share gains in the antiviral market. Cayston for chronic pulmonary infections in patients with cystic fibrosis was granted conditional marketing authorization in Europe. Expenses were reduced more than anticipated.

Atripla and Truvada demand in the U.S. were particularly high.

Non-GAAP net income was $730 million or $0.78 per share, up 42% y/y.

Product sales were $1.65 billion. $805 million U.S. anti-viral product sales. Royalty and other collaboration revenue was $152.4 million, mainly from increased Tamflu royalties of $113.5 million.

Revenues by product (millions):
y/y increase 13%



$860.6 million in operating cash flow. $200 million was used to pay down half of credit facility. Cash balance was $3.29 billion. Stock buy back program continues.

Foreign exchange impact was negative $51 million for revenues, negative $22 million for pre-tax earnings.

Inventories at distributors returned to normal levels.

571,000 U.S. patients are on anti-retroviral therapy. 180,000 are on Atripla, and it had about 50% of treatment-naive patients. In Europe Truvada led. Atripla being rapidly adopted in France, set for launch in three more nations soon.

Viread being rapidly adopted for Hepatitis B.

Ranexa for chronic angina sales force hired, trained, and released to the field.

Darusentan for resistant hypertension pivotal Phase III data demonstrating efficacy was published.

Cayston (Aztreonam Lysine) pathway to regulatory approval in the United States is being developed. It has already received conditional marketing approval in Canada.

GS91-90 being trialed for Hepatitis C, but refocussing on combining with GS92-56; not releasing data yet.


Sales guidance versus inventory? In Q2 there was a 4 day buildup due to anticipated price increases. Back to normal now. $6.35 billion guidance is actually up $150 million for prior guidance for full 2009.

R&D expense guided down? We achieved lower spending by driving synergies on acquisition of CV Therapeutics. We delayed some planned trials, like one 91-90 trial. We have a lot of exciting opportunities in the pipeline, we will make wise choices investing in them.

91-90 data? We have good enough data on safety to go ahead and enter into combination studies.

Cash use going forward? We are looking at potential opportunities to in-license or acquire new therapies. We have and will continue to look at stock buy back programs. $860 million this quarter is higher than usual, and some cash is overseas so cannot be used as flexibly.

Economic impact on sales, safety net programs? Patient assistance programs have not seen increased demand over the last 5 quarters. Only increase was recently for Viread for Hepatisis B. The economy does not seem to be having an impact on our business. A new bill in Congress will extend funding for four years of treatment and increased HIV testing.

GS93-50 is very pH solubility dependent. The letter to investigators is to try to keep patient stomach pH's from being changed by antacids, etc. Study is on track and should continue.

Tamiflu thoughts? We have to leave that to Roche. We are pleased with Roche's efforts.

OpenIcon Analyst Conference Summaries Main Page

Gilead Investor Relations page

More Gilead analyst conference summaries


More Analyst Conference Pages:


Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2009 William P. Meyers